CapsoVision (CV) Asset Writedowns and Impairment (2024)

CapsoVision (CV) reported Asset Writedowns and Impairment of $7000.0 for Q4 2024, up 600.0% sequentially from $1000.0 in Q3 2024.

CapsoVision (CV) Asset Writedowns and Impairment (2024) Analysis & Trends

CapsoVision (CV) has 1 years of Asset Writedowns and Impairment data on file, last reported at $7000.0 in Q4 2024.

For the quarter ending Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to $7000.0; the trailing twelve-month figure through Dec 2025 stood at $8000.0 (changed N/A YoY), and the FY2025 full-year result was $11000.0, up 37.5% from the prior year.
Asset Writedowns and Impairment climbed to $7000.0 in Q4 2024, from $1000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $7000.0 in Q4 2024 to a low of $1000.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	183.80 Bn	176.50 Bn	6.27 Bn
2	Stryker	128.84 Bn	125.96 Bn	3.81 Bn
3	Medtronic	108.59 Bn	99.37 Bn	6.41 Bn
4	Boston Scientific	68.51 Bn	67.06 Bn	3.61 Bn
5	Edwards Lifesciences	48.18 Bn	44.51 Bn	1.29 Bn
6	Dexcom	28.40 Bn	27.28 Bn	750.30 Mn
7	GE HealthCare Technologies	28.16 Bn	25.88 Bn	1.98 Bn
8	Smith & Nephew	26.89 Bn	26.31 Bn	-
9	Koninklijke Philips	24.66 Bn	21.54 Bn	2.07 Bn
10	CapsoVision	164.52 Mn	154.41 Mn	1.95 Mn

Download Data